Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
Advances in the Diagnosis, Prognosis and Treatment of Diffuse Large...
share announcement

Advances in the Diagnosis, Prognosis and Treatment of Diffuse Large B-cell Lymphoma

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 1920

Special Issue Editor

Dr. Gustavo Tapia

E-Mail Website
Guest Editor
Department of Pathology, Hospital Germans Trias i Pujol, Universidad Autonoma de Barcelona, 08193 Barcelona, Spain
Interests: hematopathology; lymphoma diagnosis; molecular pathology; lymphomagenesis; HIV-related lymphomas
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin (NHL) lymphoma and constitutes 25–35% of adult NHL in developed countries. In recent years, different morphological variants, molecular subtypes, and clinical–biological entities with an impact on prognosis and treatment have been described. However, there is still a group of DLBCL with heterogeneous features, and a better understanding of their biology is necessary for a precise diagnosis, prognostication, and personalized treatment.

In this Special issue, we aim to collect original and review articles focusing on recent advances in the diagnosis, molecular biology, prognostic factors, and management of DLBCL. We hope that this issue will help in further understanding the biology of DLBCL.

You may choose our Joint Special Issue in Cancers.

Dr. Gustavo Tapia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • no-Hodgkin lymphoma
  • diffuse large B-cell lymphoma
  • DLBCL
  • lymphoma treatment
  • lymphoma diagnosis
  • lymphoma prognosis
  • lymphoma biology

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1531 KiB  
Article
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma
by Katja Seipel, Michèle Frey, Henning Nilius, Dilara Akhoundova, Yara Banz, Ulrike Bacher and Thomas Pabst
Curr. Oncol. 2023, 30(12), 10463-10476; https://0-doi-org.brum.beds.ac.uk/10.3390/curroncol30120762 - 13 Dec 2023
Viewed by 1352
Abstract
Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of [...] Read more.
Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to a gain of function of PPM1D/Wip1 phosphatase, impairing p53-dependent G1 checkpoint and promoting cell proliferation. The presence of PPM1D mutations has been correlated with reduced response to standard chemotherapy in lymphoma patients. In this study, we analyzed the impact of low-frequency PPM1D mutations on the safety and efficacy of CD19-targeted CAR T-cell therapy in a cohort of 85 r/r DLBCL patients. In this cohort, the prevalence of PPM1D gene mutations was 20% with a mean variant allele frequency (VAF) of 0.052 and a median VAF of 0.036. CAR T-induced cytokine release syndrome (CRS) and immune effector cell-associated neuro-toxicities (ICANS) occurred at similar frequencies in patients with and without PPM1D mutations. Clinical outcomes were globally worse in the PPM1D mutated (PPM1Dmut) vs. PPM1D wild type (PPM1Dwt) subset. While the prevalent treatment outcome within the PPM1Dwt subgroup was complete remission (56%), the majority of patients within the PPM1Dmut subgroup had only partial remission (60%). Median progression-free survival (PFS) was 3 vs. 12 months (p = 0.07) and median overall survival (OS) was 5 vs. 37 months (p = 0.004) for the PPM1Dmut and PPM1Dwt cohort, respectively. Our data suggest that the occurrence of PPM1D mutations in the context of CH may predict worse outcomes after CD19-targeted CAR T-cell therapy in patients with r/r DLBCL. Full article
(This article belongs to the Special Issue Advances in the Diagnosis, Prognosis and Treatment of Diffuse Large B-cell Lymphoma)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop